



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Deruxtecan

Cat. No.:	HY-13631E
CAS No.:	1599440-13-7
Molecular Formula:	C ₅₂ H ₅₆ FN ₉ O ₁₃
Molecular Weight:	1034.05
Target:	Drug-Linker Conjugates for ADC
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	-20°C, protect from light, stored under nitrogen
	* The compound is unstable in solutions, freshly prepared is recommended.



SOLVENT & SOLUBILITY

In Vitro	DMF : 100 mg/mL (96.71 mM; Need ultrasonic) DMSO : 73.33 mg/mL (70.92 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent Concentration Mass	1 mg	5 mg	10 mg
		1 mM	0.9671 mL	4.8354 mL	9.6707 mL
		5 mM	0.1934 mL	0.9671 mL	1.9341 mL
		10 mM	0.0967 mL	0.4835 mL	0.9671 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 1.75 mg/mL (1.69 mM); Suspended solution; Need ultrasonic				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 1.75 mg/mL (1.69 mM); Suspended solution; Need ultrasonic				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.75 mg/mL (1.69 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and amaleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
IC ₅₀ & Target	Camptothecins
In Vitro	Antibody-drug conjugates deliver anticancer agents selectively and efficiently to tumor tissue and have significant antitumor efficacy with a wide therapeutic window ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Clin Cancer Res. 2023 Jun 6;CCR-23-0103.
- J Control Release. 2024 Feb 13;367:779-790.
- Int J Nanomedicine. 2025 Jan 17;20:723-739.
- Cancer Sci. 2024 Sep 25.
- Mol Cancer Ther. 2024 Jul 31.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1.

[2]. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA